Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
Author:
Publisher
Elsevier BV
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference37 articles.
1. Biologics in SLE: towards new approaches;van Vollenhoven;Best Pract Res Clin Rheumatol,2013
2. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force;van Vollenhoven;Ann Rheum Dis,2014
3. Prolonged clinical remission in patients with systemic lupus erythematosus;Steiman;J Rheumatol,2014
4. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS);van Vollenhoven;Ann Rheum Dis,2017
5. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort;Petri;Arthritis Rheumatol,2018
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials;The Lancet Rheumatology;2024-08
2. Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health‐Related Quality of Life;Arthritis Care & Research;2024-02-29
3. Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up;Rheumatology;2024-02-24
4. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression;Annals of the Rheumatic Diseases;2024-01-17
5. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus;Annals of the Rheumatic Diseases;2023-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3